Investigational drug · Phase 3
HS-10382
Also called: MK-4208, Tern-701
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "HS-10382"
First trial start
2024
Mar 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10382", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Myeloid Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Chronic Myeloid Leukemia, Chronic Phase
Approved drugs for the same conditions: Chronic myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10382" as an intervention, largest first.
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07885293 · 408 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: HS-10382; Imatinib and 3 more · For: Chronic Myeloid Leukemia
Sites: Wuhan, China
- A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)Pivotal-lookingRecruiting
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT06163430 · 330 participants (planned) · Start Mar 26, 2024 · Primary completion Nov 30, 2029
Drug: MK-4208 · For: Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Chronic Myeloid Leukemia, Chronic Phase; Chronic Myeloid Leukemia
Sites: Birmingham, Alabama; Gilbert, Arizona; Orange, California · 54 sites in all
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)Pivotal-lookingCompleted
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT07838987 · 196 participants · Start Dec 21, 2023 · Primary completion Jun 30, 2026
Drug: Embibatinib; Rabeprazole and 10 more · For: Healthy
Sites: Millcreek, Utah
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05367700 · 108 participants (planned) · Start Apr 28, 2022 · Primary completion Dec 30, 2024
Drug: HS-10382(Part 1: Dose escalation); HS-10382(Part 2: Dose expansion) · For: CML, Chronic Phase; CML, Accelerated Phase
Sites: Wuhan, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06530810 · 100 participants (planned) · Start Jul 31, 2024 · Primary completion May 8, 2026
Drug: HS-10382+Flumatinib · For: Chronic Myelogenous Leukemia; CML Chronic Phase; CML Accelerated Phase
- A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy ParticipantsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07933224 · 32 participants (planned) · Start Nov 2026 · Primary completion Feb 2027
Drug: HS-10382 · For: Healthy Volunteers
Sites: Hefei, China
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT07839000 · 8 participants · Start Feb 25, 2026 · Primary completion Apr 3, 2026
Drug: TERN-701 · For: Healthy
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoforms.
Lagonik E, Quinlan LJ, Page EC, et al. · Exp Hematol Oncol 2026
- Emerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.
Motomura Y, Sasaki K · Int J Hematol 2026
- Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms.
Haddad FG, Kantarjian H · Blood Cancer J 2026
- Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.
Naderi Z, Sadras T, Branford S, et al. · Curr Hematol Malig Rep 2026
- Advances of next-generation STAMP inhibitors in chronic myeloid leukemia.
Costa A, Breccia M · Expert Opin Investig Drugs 2026
- Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain.
Lagonik E, Page EC, Bruning JB, et al. · Blood Neoplasia 2025
Also in development for Chronic Myeloid Leukemia
- OlverembatinibPhase 34 trials
Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia
- TGRX-678Phase 32 trials
Shenzhen TargetRx Co., Ltd. · Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myeloid Leukemia
- FlumatinibPhase 31 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Chronic Myeloid Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.